2026 pediatric cancer guideline maintains levofloxacin and antifungal prophylaxis recommendations
Future research should refine prophylaxis indications for different patient subgroups.
The publication
The 2026 Pediatric Oncology Group of Ontario clinical practice guideline maintains strong recommendations for levofloxacin and antifungal prophylaxis in specific pediatric cancer and transplant patients. The update incorporates 13 new randomized trials published since 2019 into a total evidence base of 195 trials.
Who the findings apply to
The guideline applies to pediatric patients with cancer and hematopoietic cell transplantation recipients.
Specific recommendations address pediatric patients with acute myeloid leukemia and relapsed acute lymphoblastic leukemia for antibacterial prophylaxis.
Antifungal prophylaxis recommendations apply to pediatric patients with acute myeloid leukemia and allogeneic hematopoietic cell transplantation recipients.
Why this matters
The guideline harmonizes procedures and recommendations across antibacterial and antifungal prophylaxis for pediatric patients with cancer and hematopoietic cell transplantation recipients. By updating systematic reviews of randomized clinical trials using the Grading of Recommendations Assessment, Development and Evaluation approach, the panel ensures recommendations reflect the most current evidence for infection prevention in these vulnerable populations.
What the study found
The panel maintained a conditional recommendation to consider antibacterial prophylaxis in pediatric patients with acute myeloid leukemia and relapsed acute lymphoblastic leukemia.
A strong recommendation to use levofloxacin when antibacterial prophylaxis is planned was maintained.
A new conditional recommendation was introduced to consider using no antibacterial prophylaxis in patients unable to receive levofloxacin.
Strong recommendations to use antifungal prophylaxis in pediatric patients with acute myeloid leukemia and allogeneic hematopoietic cell transplantation recipients were maintained.
A strong recommendation to use an echinocandin or a mold-active azole when antifungal prophylaxis is planned was maintained.
Three new good practice statements were added, focusing on drug interactions, infection prevention practices, and monitoring infection epidemiology.
What the result does not establish
The update identified 13 new randomized trials published since 2019, resulting in 195 total trials evaluated.
The authors conclude that future research should refine prophylaxis indications for different patient subgroups.
Authors’ conclusion
“This update consolidates and harmonizes CPGs for systemic antibacterial and antifungal prophylaxis in pediatric patients with cancer and HCT patients. Future research should refine prophylaxis indications for different patient subgroups.”
Study and sources
Clinical Practice Guideline for Systemic Antibacterial and Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Cell Transplant Recipients: 2026 Update
Guidelines & recommendations · Journal of clinical oncology · 2026-10-02
Sources and limitations
- PubMed record PMID 42826360 (PubMed / NLM · 2026-10-03)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


